Suchergebnisse - "Fajgenbaum, David C"

PubPharm (8)

1

Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome

enthalten in: Annals of hematology | 2016

von Behnia, F. | Elojeimy, S. | Matesan, M. | +1

2

Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome

enthalten in: Annals of hematology | 2016

von Behnia, F. | Elojeimy, S. | Matesan, M. | +1

3

Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome

enthalten in: Annals of hematology | 2016

von Behnia, F. | Elojeimy, S. | Matesan, M. | +1

4

The collaborative network approach : a new framework to accelerate Castleman's disease and other rare disease research

enthalten in: The Lancet. Haematology | 2016

von Fajgenbaum, D. | Ruth, J. | Kelleher, D. | +1

CommentOn: Lancet Haematol. 2016 Apr;3(4):e163-75. - PMID 27063975

5

Idiopathic multicentric Castleman's disease : a systematic literature review

enthalten in: The Lancet. Haematology | 2016

von Liu, A. | Nabel, C. | Finkelman, B. | +7

CommentIn: Lancet Haematol. 2016 Apr;3(4):e150-2. - PMID 27063967

6

Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease

enthalten in: American journal of hematology | 2016

von Iwaki, N. | Fajgenbaum, D. | Nabel, C. | +19

7

Siltuximab : a targeted therapy for idiopathic multicentric Castleman disease

enthalten in: Immunotherapy | 2016

von Fajgenbaum, D. | Kurzrock, R.

8

Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV‐8‐negative multicentric Castleman disease

enthalten in: American journal of hematology | 2016

von Moro, H. | Kondo, E. | Nakamura, N. | +19

1
[1]